{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:43:33Z","timestamp":1792669413682,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11883-019-0816-4","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T14:02:29Z","timestamp":1574690549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["The Current Literature on Bioabsorbable Stents: a Review"],"prefix":"10.1007","volume":"21","author":[{"given":"Wally A.","family":"Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharam J.","family":"Kumbhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"816_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(78)90500-7","volume":"1","author":"A Gruntzig","year":"1978","unstructured":"Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;1:263.","journal-title":"Lancet"},{"issue":"1","key":"816_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/0002-8703(95)90055-1","volume":"129","author":"RL Mueller","year":"1995","unstructured":"Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. Am Heart J. 1995;129(1):146\u201372.","journal-title":"Am Heart J"},{"key":"816_CR3","unstructured":"Kumbhani DJ, Bhatt DL. Evolution of periprocedural pharmacotherapy in patients undergoing percutaneous coronary intervention, in Textbook of interventional cardiology: a global perspective, K. SR, Editor. 2017, JP Medical Ltd."},{"issue":"8","key":"816_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJM199408253310801","volume":"331","author":"PW Serruys","year":"1994","unstructured":"Serruys PW, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489\u201395.","journal-title":"N Engl J Med"},{"issue":"8","key":"816_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJM199408253310802","volume":"331","author":"DL Fischman","year":"1994","unstructured":"Fischman DL, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331(8):496\u2013501.","journal-title":"N Engl J Med"},{"issue":"12","key":"816_CR6","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0735-1097(02)02597-4","volume":"40","author":"DE Cutlip","year":"2002","unstructured":"Cutlip DE, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40(12):2082\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"816_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.tcm.2014.07.004","volume":"24","author":"BD Gogas","year":"2014","unstructured":"Gogas BD, et al. Novel drug-eluting stents for coronary revascularization. Trends Cardiovasc Med. 2014;24(7):305\u201313.","journal-title":"Trends Cardiovasc Med"},{"key":"816_CR8","doi-asserted-by":"crossref","unstructured":"Stefanini GG, Holmes DR. Drug-eluting coronary-artery stents. 2013;368(3):254\u201365.","DOI":"10.1056\/NEJMra1210816"},{"issue":"3","key":"816_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa032441","volume":"350","author":"GW Stone","year":"2004","unstructured":"Stone GW, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221\u201331.","journal-title":"N Engl J Med"},{"issue":"23","key":"816_CR10","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa012843","volume":"346","author":"MC Morice","year":"2002","unstructured":"Morice MC, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773\u201380.","journal-title":"N Engl J Med"},{"key":"816_CR11","unstructured":"Kumbhani DJ, B.A., Bhatt DL, Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis? Indian Heart J , 2007. 59: p. B113-B117."},{"issue":"7","key":"816_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.106.686048","volume":"116","author":"F Airoldi","year":"2007","unstructured":"Airoldi F, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745\u201354.","journal-title":"Circulation"},{"issue":"12","key":"816_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.amjmed.2006.01.023","volume":"119","author":"AA Bavry","year":"2006","unstructured":"Bavry AA, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119(12):1056\u201361.","journal-title":"Am J Med"},{"key":"816_CR14","doi-asserted-by":"crossref","unstructured":"Stone GW. et al, Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. 2010;362(18):1663\u201374.","DOI":"10.1056\/NEJMoa0910496"},{"issue":"23","key":"816_CR15","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","volume":"65","author":"T Palmerini","year":"2015","unstructured":"Palmerini T, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65(23):2496\u2013507.","journal-title":"J Am Coll Cardiol"},{"key":"816_CR16","doi-asserted-by":"crossref","unstructured":"Mauri L. et al, Stent thrombosis in randomized clinical trials of drug-eluting stents. 2007;356(10):1020\u20139.","DOI":"10.1056\/NEJMoa067731"},{"issue":"6","key":"816_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jacc.2016.11.055","volume":"69","author":"AM Gall\u00f8e","year":"2017","unstructured":"Gall\u00f8e AM, et al. 10-year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents. J Am Coll Cardiol. 2017;69(6):616\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"816_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","volume":"48","author":"M Joner","year":"2006","unstructured":"Joner M, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193\u2013202.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"816_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jcmg.2008.12.026","volume":"2","author":"T Higo","year":"2009","unstructured":"Higo T, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. JACC Cardiovasc Imaging. 2009;2(5):616\u201324.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"15","key":"816_CR20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jacc.2011.12.016","volume":"59","author":"IT Meredith","year":"2012","unstructured":"Meredith IT, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated,everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59(15):1362\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"816_CR21","doi-asserted-by":"crossref","unstructured":"Kereiakes DJ, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial. Circ Cardiovasc Interv. 2015;8(4).","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372"},{"issue":"13","key":"816_CR22","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jacc.2011.06.027","volume":"58","author":"RA Byrne","year":"2011","unstructured":"Byrne RA, et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol. 2011;58(13):1325\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"816_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.114.013520","volume":"131","author":"C Kaiser","year":"2015","unstructured":"Kaiser C, et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation. 2015;131(1):74\u201381.","journal-title":"Circulation"},{"issue":"3","key":"816_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jacc.2013.04.045","volume":"62","author":"M Natsuaki","year":"2013","unstructured":"Natsuaki M, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;62(3):181\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"816_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jcin.2016.12.002","volume":"10","author":"G El-Hayek","year":"2017","unstructured":"\u2022 El-Hayek G, et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv. 2017;10(5):462\u201373 Demonstrates the favorable profile of durable-polymer drug eluting stents, which set the stage for the advent of bioresorbable vascular scaffolds.","journal-title":"JACC Cardiovasc Interv"},{"issue":"19","key":"816_CR26","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1161\/CIRCULATIONAHA.110.000901","volume":"125","author":"S Nishio","year":"2012","unstructured":"Nishio S, et al. Long-term (>10\u00a0Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation. 2012;125(19):2343\u201353.","journal-title":"Circulation"},{"issue":"6","key":"816_CR27","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.jcin.2013.11.024","volume":"7","author":"JP Lane","year":"2014","unstructured":"Lane JP, et al. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. J Am Coll Cardiol Intv. 2014;7(6):688\u201395.","journal-title":"J Am Coll Cardiol Intv"},{"key":"816_CR28","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1016\/j.jacc.2017.09.1106","volume":"70","author":"GW Stone","year":"2017","unstructured":"Stone GW, Abizaid A, Onuma Y, et al. Effect of technique on outcomes following bioresorbable vascular scaffold implantation: analysis from the ABSORB trials. J Am Coll Cardiol. 2017;70:2863\u201374.","journal-title":"J Am Coll Cardiol"},{"key":"816_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.116.021539","volume":"134","author":"DJ Kereiakes","year":"2016","unstructured":"Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable vascular scaffolds for coronary revascularization. Circulation. 2016;134:168\u201382.","journal-title":"Circulation"},{"issue":"10157","key":"816_CR30","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","volume":"392","author":"GW Stone","year":"2018","unstructured":"Stone GW, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392(10157):1530\u201340.","journal-title":"Lancet"},{"issue":"9962","key":"816_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","volume":"385","author":"PW Serruys","year":"2015","unstructured":"Serruys PW, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43\u201354.","journal-title":"Lancet"},{"issue":"5","key":"816_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ahj.2012.08.010","volume":"164","author":"R Diletti","year":"2012","unstructured":"Diletti R, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design. Am Heart J. 2012;164(5):654\u201363.","journal-title":"Am Heart J"},{"issue":"21","key":"816_CR33","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","volume":"66","author":"R Gao","year":"2015","unstructured":"Gao R, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66(21):2298\u2013309.","journal-title":"J Am Coll Cardiol"},{"issue":"47","key":"816_CR34","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/eurheartj\/ehv435","volume":"36","author":"Investigators, t.A.J","year":"2015","unstructured":"Investigators, t.A.J, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332\u201342.","journal-title":"Eur Heart J"},{"issue":"23","key":"816_CR35","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","volume":"70","author":"DJ Kereiakes","year":"2017","unstructured":"\u2022 Kereiakes DJ, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial. J Am Coll Cardiol. 2017;70(23):2852\u201362 Highlights the signficant safety concerns of the ABSORB trial, published immediately befor the stent was pulled from all markets.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"816_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","volume":"137","author":"ZA Ali","year":"2018","unstructured":"Ali ZA, et al. Three-year outcomes with the Absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation. 2018;137(5):464\u201379.","journal-title":"Circulation"},{"issue":"25","key":"816_CR37","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1016\/j.jacc.2017.04.011","volume":"69","author":"S Sorrentino","year":"2017","unstructured":"Sorrentino S, et al. Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents. J Am Coll Cardiol. 2017;69(25):3055\u201366.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"816_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1161\/01.CIR.94.3.266","volume":"94","author":"K Kugiyama","year":"1996","unstructured":"Kugiyama K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation. 1996;94(3):266\u201371.","journal-title":"Circulation"},{"issue":"8","key":"816_CR39","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jcin.2016.12.020","volume":"10","author":"D Dudek","year":"2017","unstructured":"Dudek D, et al. Vasomotor response to nitroglycerine over 5\u00a0years follow-up after everolimus-eluting bioresorbable scaffold implantation. JACC Cardiovasc Interv. 2017;10(8):786\u201395.","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"816_CR40","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s10439-009-9719-9","volume":"37","author":"JM Jimenez","year":"2009","unstructured":"Jimenez JM, Davies PF. Hemodynamically driven stent strut design. Ann Biomed Eng. 2009;37(8):1483\u201394.","journal-title":"Ann Biomed Eng"},{"issue":"19","key":"816_CR41","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.jacc.2017.09.014","volume":"70","author":"K Yamaji","year":"2017","unstructured":"\u2022\u2022 Yamaji K, et al. Mechanisms of very late bioresorbable scaffold thrombosis: the INVEST Registry. J Am Coll Cardiol. 2017;70(19):2330\u201344 Explores various mechanisms of thromobiss in bioresorbable stents, using optical coherence tomography.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-019-0816-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-019-0816-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-019-0816-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:33:50Z","timestamp":1606178030000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-019-0816-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s11883-019-0816-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"25 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Wally A. Omar and Dharam J. Kumbhani declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"54"}}